M
MBX Biosciences
Biotech & Life Sciences · Carmel, United States · Founded 2018 · IPO 2024
Advancing potential breakthrough medicines for endocrine diseases of substantial medical need MoreLess
MBX Biosciences is a clinical-stage biopharmaceutical company that specializes in the discovery and development of therapies for endocrine and metabolic diseases. The company's approach is centered around its proprietary Precision Endocrine Peptide™ (PEP™) platform, which enables the creation of novel peptide-based drug candidates.
Operating in the biopharmaceutical sector, MBX Biosciences focuses on conditions with unmet medical needs. The company's business model involves advancing its therapeutic candidates through the clinical trial process. As a clinical-stage company, its primary activities include research and development, conducting clinical trials to establish the safety and efficacy of its drug candidates, and seeking regulatory approval. The company went public with an IPO on September 13, 2024, and its stock is traded under the ticker MBX. Its revenue generation model is typical for a biopharmaceutical company at this stage, relying on investment capital to fund its R&D efforts. Future revenue will be dependent on the successful commercialization of its products, which may involve partnerships or licensing agreements with larger pharmaceutical companies.
Keywords: biopharmaceutical, peptide therapies, endocrine diseases, metabolic diseases, clinical-stage, PEP platform, rare diseases, drug development, public company, therapeutics
Company overview
MBX Biosciences company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2018
- Headquarters
- Carmel, United States
- Employees
- 78
- Open positions
- 17
- Dealroom signal
- 92.8
Valuation & funding
MBX Biosciences funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Sep 2025 | $200M | — | Undisclosed | ↗ |
| IPOOther financing | Sep 2024 | $188M | $188M | Undisclosed | ↗ |
| SERIES COther financing | Aug 2024 | $64M | $575M | NEA · Wellington Management · Norwest Venture Partners · OrbiMed | ↗ |
| SERIES BOther financing | Nov 2022 | $115M | $460M | Norwest Venture Partners · OrbiMed · Wellington Management · NEA | ↗ |
| SERIES AOther financing | Jul 2020 | $35M | $138M | NEA · Frazier Healthcare Partners · Twilight Venture Partners · BioCrossroads | — |
| DEBTDebt | Apr 2019 | Undisclosed | — | ||
| SPINOUTOther financing | Jan 2018 | Indiana University | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$98M | — |
| 2025 | $0 | — | −$98M | — |
| 2024 | $0 | — | −$68M | — |
| 2023 | $0 | — | −$32M | — |
| 2022 | $0 | — | −$25M | — |
Growth signals
MBX Biosciences website traffic
Latest recorded traffic for MBX Biosciences is 13K monthly website visits, up 8.3% over the last three months. MBX Biosciences's team grew 13% over the past year.
Hiring
Open positions at MBX Biosciences
Current openings linked to this company in Dealroom.
Comparisons
MBX Biosciences compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
MBX Biosciences's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where MBX Biosciences has talent and traffic
team presence
In the news
Latest news about MBX Biosciences
Recent press, funding announcements, and product moves mentioning MBX Biosciences — open to read from the original sources.
Market sentiment
What the market is saying about MBX Biosciences
An AI-synthesized read of the highest-engagement posts about MBX Biosciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See MBX Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.